Get the Stockscreener App
1.06
2.75%
-0.03
After Hours:
1.09
0.03
+2.83%
Cel-Sci Corp. stock is traded at $1.06, with a volume of 149.24K.
It is down -2.75% in the last 24 hours and down -1.85% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$1.09
Open:
$1.07
24h Volume:
149.24K
Relative Volume:
0.12
Market Cap:
$65.18M
Revenue:
-
Net Income/Loss:
$-32.37M
P/E Ratio:
-1.3766
EPS:
-0.77
Net Cash Flow:
$-23.22M
1W Performance:
-1.85%
1M Performance:
-1.85%
6M Performance:
-44.50%
1Y Performance:
-15.20%
1-Day Range:
$1.05
$1.10
1-Week Range:
$1.02
$1.10
52-Week Range:
$1.02
$3.23
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CVM Stock Sees Decline of Approximately -6.25% in Last Five Days - Knox Daily
How to interpret Cel-Sci Corp. (CVM)’s stock chart patterns - US Post News
Cel-Sci Corp.’s Market Journey: Closing Weak at 1.05, Down -1.87 - The Dwinnex
CEL-SCI Co. (NYSE:CVM) Position Raised by Thoroughbred Financial Services LLC - Defense World
Celonis expands alliance with Samsung for process optimisation - Yahoo! Voices
Stifel Upgrades Celestica Inc. (CLS) to Buy from Hold - Insider Monkey
Creo Sells Stake of Subsidiary to Chinese Market-Leader - Business News Wales
Celonis Expands Partnership with Samsung Fire & Marine Insurance to Optimize Processes and to Drive Value - Business Wire
Check out these key findings about Complete Solaria Inc. (CSLR) - SETE News
Trend Tracker for (CLS) - Stock Traders Daily
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Investing in Complete Solaria Inc. (CSLR) Is Getting More Attractive - Knox Daily
CVM’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Exact Sciences Debuts Positive Topline Results for Trial of Blood-Based Colorectal Cancer Screening Algorithm - Patient Care Online
Potential Price Increase for Cel-Sci Corp. (CVM) After Recent Insider Activity - Knox Daily
ESMO: Exact Sciences shows off early colorectal cancer blood test data - Fierce Biotech
Multikine shows promise in head and neck cancer study - Investing.com
Healthy Upside Potential: Celestica, Inc. (CLS) - SETE News
ESMO 2024: Exact Sciences unveils results from cancer algorithm trial - Medical Device Network
CEL-SCI Corp's (CVM) Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - StreetInsider.com
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation – Company AnnouncementFT.com - Financial Times
Exact Sciences announces data for CRC screening test - TipRanks
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 - Business Wire
Celestica Inc. (CLS): Among the Worst Performing AI Stocks of Previous Week - Insider Monkey
Creighton loses top-10 matchup, falling in fifth set to No. 4 Louisville - Kearney Hub
Global Therapeutic Vaccines Market by Method, Application and Forecast 2024-2032 - 대구포스트
Cel-Sci Corp. (CVM) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Understanding the Risks of Investing in Cel-Sci Corp. (CVM) - Knox Daily
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress - Yahoo Finance
UTHR Shares Experience Surge in Value - Knox Daily
A company insider recently bought 20,000 shares of Cel-Sci Corp. [CVM]. Should You Buy? - Knox Daily
BKNG Shares Experience Decline in Value - Knox Daily
CEL-SCI gains UK pediatric waiver for cancer treatment - Investing.com
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance - Business Wire
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance - Yahoo Finance
Wells Fargo analysts initates an Equal weight rating for GeneDx Holdings Corp (WGS) - Knox Daily
CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study - Yahoo Finance
Vanguard Group Inc. Grows Stock Position in CEL-SCI Co. (NYSE:CVM) - Defense World
CVM (CEL-SCI) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
Closing Figures Unveiled: Cel-Sci Corp. (CVM) Drop -0.87, Closes at 1.14 - The Dwinnex
Cel-Sci Corp. (CVM)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Cel-Sci: Fiscal Q3 Earnings Snapshot - CT Insider
Cel-Sci: Fiscal Q3 Earnings Snapshot - San Antonio Express-News
Cel-Sci: Fiscal Q3 Earnings Snapshot - Houston Chronicle
Cel-Sci: Fiscal Q3 Earnings Snapshot - The Washington Post
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results - Yahoo Finance
Cel-Sci: Fiscal Q3 Earnings Snapshot - The Advocate
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):